Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119392 · ClinicalTrials.gov registry record · Phase 2
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00119392 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 42 participants.
The verdict
NCT00119392, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can block find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells. Giving monoclonal antibodies, low doses of chemotherapy, such as fludarabine phosphate, and low dose total-body radiation therapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells and also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine or mycophenolate mofetil after the transplant may stop this from happening
Interventions
- BIOLOGICAL rituximab
- DRUG fludarabine phosphate
- DRUG cyclosporine
- DRUG mycophenolate mofetil
- RADIATION yttrium Y 90 ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2004-06 |
| Est. Completion | 2016-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00119392
The ClinicalTrials.gov registry entry for NCT00119392 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00119392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00119392 about?
NCT00119392 is a clinical study titled "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can block find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells. Giving monoclonal antibodies, low doses of chemotherapy, such as fludarabine phosphate, and low dose total-body ...
What is the current status of trial NCT00119392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2004-06. Estimated completion is 2016-04-23.
What interventions are being tested in trial NCT00119392?
The interventions under investigation include: rituximab (BIOLOGICAL), fludarabine phosphate (DRUG), cyclosporine (DRUG), mycophenolate mofetil (DRUG), yttrium Y 90 ibritumomab tiuxetan (RADIATION).
Who is sponsoring clinical trial NCT00119392?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.